Pharmacogenomics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Pharmacogenomics Market Report is Segmented by Technology (DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, and Other Technologies), Application (Drug Discovery, Neurology, Oncology, Pain Management, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (USD) for the Above Segments.

Pharmacogenomics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Pharmacogenomics Market Size

Pharmacogenomics Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 9.20 Billion
Market Size (2030) USD 12.38 Billion
CAGR (2025 - 2030) 6.12 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Pharmacogenomics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Pharmacogenomics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Pharmacogenomics Market Analysis

The Pharmacogenomics Market size is estimated at USD 9.20 billion in 2025, and is expected to reach USD 12.38 billion by 2030, at a CAGR of 6.12% during the forecast period (2025-2030).

The pharmacogenomics market is driven by the rising popularity of precision medicine, coupled with growing research and development expenditures on pharmacogenomics technologies, which is accelerating the development of novel products. The high incidence rate of adverse drug reactions is also driving the higher adoption of pharmacogenomics in the global market.

The increasing focus on precision medicine is expected to augment the pharmacogenomics market, as the precision medicine approach aims to integrate genetic and environmental information about diseases and their responses to treatments. For instance, in June 2023, the National Cancer Institute introduced a precision medicine initiative known as Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH), which can evaluate the different drug combinations for cancer patients based on tumor biology. With the rapid growth in digital technologies and advances in biology, the pharmacogenomics market is projected to grow significantly.

Additionally, increasing research and development spending is contributing to the adoption of pharmacogenomics and driving the market's growth. For instance, in March 2023, Allroion Therapeutics, the next-generation precision medicine company focusing on oncology and autoimmune disorders, completed a USD 50 million Series B financing round to develop upcoming clinical trials in phase I/II in China and the United States. This increase in R&D spending is expected to boost the market’s growth during the forecast period.

Sanger technology and next-generation sequencing are increasingly adopted in academic and institutional research projects. Additionally, a rise in funding and investment programs augment these entities' demand for DNA sequencing products. For instance, in January 2024, according to the National Cancer Institute, the spending on cancer research funding increased significantly from USD 6.72 billion in 2022 to USD 7.10 billion in 2023 in the United States. This data shows significant investment in genomics and personalized medicine, which is expected to impact the pharmacogenomics market's growth positively. Pharmacogenomics is also helpful in cancer treatment and has proved to improve the survival of patients. At the same time, it has also been found to reduce the unnecessary cost of unresponsive therapy by patients.

Therefore, factors such as increasing focus on precision medicine and growing research and development spending are expected to enhance the growth of the pharmacogenomics market during the forecast period. However, issues related to reimbursement and problems associated with the detection of gene variation that affects drug response may restrain the growth of the pharmacogenomics market during the forecast period.

Pharmacogenomics Industry Overview

The pharmacogenomics market is highly fragmented due to several key players. The large interest of researchers and investment in the safety and efficiency of drugs by companies are the major factors responsible for the market's growth, making it highly competitive with the presence of many key players in the pharmacogenomics market. The government is also involved in funding companies that work to develop bioinformatics technology for precision medicine research applications. Some players are Abbott Laboratories Inc., Biomerieux SA, Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Thermo Fisher Scientific, and F. Hoffman-La Roche Ltd.

Pharmacogenomics Market Leaders

  1. Thermo Fisher Scientific Inc.

  2. Abbott Laboratories Inc.

  3. F. Hoffmann-La Roche AG

  4. Bio-Rad Laboratories

  5. Biomerieux SA

  6. *Disclaimer: Major Players sorted in no particular order
Pharmacogenomics Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Pharmacogenomics Market News

  • May 2024: Oxford Nanopore Technologies introduced a new Pharmacogenomics (PGx) Beta Programme for advancing personalized medicine with the combination of Twist Bioscience’s next-generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform.
  • February 2024: Nicklaus Children's Hospital in South Florida adopted the next-generation pharmacogenomics technology, Applied Biosystems PharmacoScan Solution and GeneTitan MC Fast Scan Instrument, to develop personalized treatment plans for the patients and reduce the complications from drug interactions and side effects.

Pharmacogenomics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumption and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Focus on Precision Medicine
    • 4.2.2 Increasing Expenditure in Research and Development
    • 4.2.3 High Rate of Adverse Drug Reaction
    • 4.2.4 Enhancement of Drug Safety and Efficiency to Increase Success Rates in Pharmaceutical R&D
  • 4.3 Market Restraints
    • 4.3.1 Difficulties in Detecting Gene Variation that Affect Drug Response
    • 4.3.2 Reimbursement Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Technology
    • 5.1.1 DNA Sequencing
    • 5.1.2 Microarray
    • 5.1.3 Polymerase Chain Reaction
    • 5.1.4 Electrophoresis
    • 5.1.5 Mass Spectrometry
    • 5.1.6 Other Technologies
  • 5.2 By Application
    • 5.2.1 Drug Discovery
    • 5.2.2 Neurology
    • 5.2.3 Oncology
    • 5.2.4 Pain Management
    • 5.2.5 Other Applications
  • 5.3 By Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories Inc.
    • 6.1.2 Agilent Technologies Inc.
    • 6.1.3 Becton, Dickinson and Company
    • 6.1.4 Biomerieux
    • 6.1.5 Bio-Rad Laboratories Inc.
    • 6.1.6 Eurofins Scientific
    • 6.1.7 F. Hoffmann-La Roche Ltd
    • 6.1.8 Illumina Inc.
    • 6.1.9 Merck KgAA
    • 6.1.10 Pacific Biosciences of California Inc.
    • 6.1.11 PerkinElmer Inc.
    • 6.1.12 Qiagen NV
    • 6.1.13 Thermo Fisher Scientific Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Pharmacogenomics Industry Overview

As per the scope of this report, pharmacogenomics provides accurate insights into making clinical decisions and determining the most effective treatment by varying the dosages of drugs. The field of pharmacogenomics is predicted to treat a wide range of health problems, including cardiovascular diseases, Alzheimer's disease, cancer, HIV/AIDS, and asthma. The pharmacogenomics market is segmented by technology, application, and geography. By technology, the market is segmented into DNA sequencing, microarray, polymerase chain reaction, electrophoresis, mass spectrometry, and other technologies. By application, the market is segmented into drug discovery, neurology, oncology, pain management, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market size is provided in terms of value (USD).

By Technology DNA Sequencing
Microarray
Polymerase Chain Reaction
Electrophoresis
Mass Spectrometry
Other Technologies
By Application Drug Discovery
Neurology
Oncology
Pain Management
Other Applications
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Pharmacogenomics Market Research FAQs

How big is the Pharmacogenomics Market?

The Pharmacogenomics Market size is expected to reach USD 9.20 billion in 2025 and grow at a CAGR of 6.12% to reach USD 12.38 billion by 2030.

What is the current Pharmacogenomics Market size?

In 2025, the Pharmacogenomics Market size is expected to reach USD 9.20 billion.

Who are the key players in Pharmacogenomics Market?

Thermo Fisher Scientific Inc., Abbott Laboratories Inc., F. Hoffmann-La Roche AG, Bio-Rad Laboratories and Biomerieux SA are the major companies operating in the Pharmacogenomics Market.

Which is the fastest growing region in Pharmacogenomics Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Pharmacogenomics Market?

In 2025, the North America accounts for the largest market share in Pharmacogenomics Market.

What years does this Pharmacogenomics Market cover, and what was the market size in 2024?

In 2024, the Pharmacogenomics Market size was estimated at USD 8.64 billion. The report covers the Pharmacogenomics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Pharmacogenomics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Pharmacogenomics Industry Report

The Pharmacogenomics Market Report provides a comprehensive industry analysis, focusing on various technologies such as DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, and other technologies. The report also delves into applications including Drug Discovery, Neurology, Oncology, Pain Management, and other applications. The geographical segmentation covers North America, Europe, Asia-Pacific, Middle East and Africa, and South America.

The market analysis highlights the market size and market value, offering an in-depth market overview and market segmentation. This industry report includes market data and industry statistics, providing a detailed industry outlook and market forecast. The market review also covers market growth and industry trends, showcasing the market leaders in this sector.

In addition to the market predictions, the report provides industry research and industry information, which are crucial for understanding the market dynamics. The industry sales and industry size are also discussed, giving a clear picture of the market's potential. The report example and report pdf are available for further reference, ensuring that all relevant industry research and market trends are covered.

Overall, the Pharmacogenomics Market Report is a valuable resource for anyone looking to gain insights into this evolving market. The report's comprehensive analysis and detailed industry outlook make it an essential tool for market leaders and research companies.